Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].

Blasco AJ, Arribas JR, Clotet B, Domingo P, González-García J, López-Bernaldo JC, Llibre JM, Lozano F, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM.

Enferm Infecc Microbiol Clin. 2011 Dec;29(10):721-30. doi: 10.1016/j.eimc.2011.08.003. Epub 2011 Oct 19. Spanish.

PMID:
22014894
2.

[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].

Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM; en representación de GESIDA.

Enferm Infecc Microbiol Clin. 2012 Jun;30(6):283-93. doi: 10.1016/j.eimc.2012.02.016. Epub 2012 Apr 22. Spanish.

PMID:
22525829
3.

[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].

Blasco AJ, Llibre JM, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM; en representación de GESIDA.

Enferm Infecc Microbiol Clin. 2013 Nov;31(9):568-78. doi: 10.1016/j.eimc.2013.06.002. Epub 2013 Aug 20. Spanish.

PMID:
23969276
4.

Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Blasco AJ, Llibre JM, Berenguer J, González-García J, Knobel H, Lozano F, Podzamczer D, Pulido F, Rivero A, Tuset M, Lázaro P, Gatell JM; GESIDA ART Cost-efficacy Study Group.

Enferm Infecc Microbiol Clin. 2015 Mar;33(3):156-65. doi: 10.1016/j.eimc.2014.05.016. Epub 2014 Aug 28.

PMID:
25175171
5.

Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, Lázaro P, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Tuset M, Gatell JM; GeSIDA Antiretroviral Therapy Cost-efficacy Study Group.

Enferm Infecc Microbiol Clin. 2015 Aug 27. pii: S0213-005X(15)00287-6. doi: 10.1016/j.eimc.2015.07.012. [Epub ahead of print]

PMID:
26321131
6.

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults.

Gatell JM, Arribas JR, Lázaro P, Blasco A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19603. doi: 10.7448/IAS.17.4.19603. eCollection 2014.

7.

Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.

Sánchez-de la Rosa R, Herrera L, Moreno S.

Clin Ther. 2008 Feb;30(2):372-81. doi: 10.1016/j.clinthera.2008.02.009.

PMID:
18343275
9.

Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.

Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.

J Med Econ. 2015;18(10):763-76. doi: 10.3111/13696998.2015.1046878.

PMID:
25934146
10.

Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines.

Colombo GL, Di Matteo S, Antinori A, Medaglia M, Murachelli S, Rizzardini G.

Clinicoecon Outcomes Res. 2013 Oct 3;5:489-96. doi: 10.2147/CEOR.S48246. Review.

11.

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults.

Gatell Artigas JM, Arribas López JR, Lázaro Y de Mercado P, Blasco Bravo AJ.

Enferm Infecc Microbiol Clin. 2015 Mar 3. pii: S0213-005X(15)00067-1. doi: 10.1016/j.eimc.2015.01.018. [Epub ahead of print]

PMID:
25749416
12.

[Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2012 Jun;30(6):e1-89. doi: 10.1016/j.eimc.2012.03.006. Epub 2012 May 23. Spanish.

PMID:
22633764
13.

Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.

Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19605. doi: 10.7448/IAS.17.4.19605. eCollection 2014.

14.

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A; AI266073 Study Group.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74. doi: 10.1097/QAI.0b013e3181a572cf.

PMID:
19357529
15.

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE.

AIDS. 2008 Oct 1;22(15):2025-33. doi: 10.1097/QAD.0b013e3283103ce6.

17.

[Budget impact analysis of antiretroviral therapy. A reflection based on the GESIDA guidelines].

Grupo de trabajo de la Cohorte VACH.

Gac Sanit. 2012 Nov-Dec;26(6):541-6. doi: 10.1016/j.gaceta.2012.01.015. Epub 2012 Apr 11. Spanish.

18.

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40.

PMID:
17057609
19.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team.

AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2.

PMID:
19542866
20.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;6:CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk